Literature DB >> 15146294

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.

Joanna Galea-Lauri1, James W Wells, David Darling, Phillip Harrison, Farzin Farzaneh.   

Abstract

Dendritic cells (DCs) primed with tumor antigens (Ags) can stimulate tumor rejection. This study was aimed at evaluating the polarization of T-cell responses using various DC Ag-priming strategies for vaccination purposes. DCs cocultured with irradiated "apoptotic" tumor cells, DC-tumor fusions, and DCs pulsed with freeze-thaw tumor lysate Ags served as Ag-primed DCs, with EG7 tumor cells (class II negative) expressing OVA as the model Ag. DCs loaded with class I- and class II-restricted OVA synthetic peptides served as controls. Primed DCs were assessed by the in vitro activation of B3Z OVA-specific CD8 T cells and the proliferation of OVA-specific CD8 and CD4 T cells from OT-I and OT-II TCR transgenic mice, respectively. In vivo responses were measured by tumor regression following treatment with Ag-primed DCs and by CTL assays. Quantification of IL-2, IL-4, IL-5, IFN-gamma, and TNF-alpha by cytometric bead array (CBA) assay determined the polarization of TH1/TH2 responses, whereas H-2 Kb/SIINFEKL tetramers monitored the expansion of OVA-specific T cells. DC-EG7 hybrids stimulated both efficient class I and class II OVA responses, showing that DC-tumor hybrids are also capable of class II cross-presentation. The hybrids also induced the most potent CTLs, offered the highest protection against established EG7 tumors and also induced the highest stimulation of IFN-gamma and TNF-alpha production. DCs cocultured with irradiated EG7 were also effective at inducing OVA-specific responses, however with slightly reduced potency to those evoked by the hybrids. DCs loaded with lysates Ags were much less efficient at stimulating any of the OVA-specific T-cell responses, showed very little antitumor protection, and stimulated a weak TH1 response, overbalanced by an IL-5 TH2 response. The strategy of Ag-loading clearly influences the ability of DCs to polarize T cells for a TH1/TH2 response and thus determines the outcome of the elicited immune response, during various vaccination protocols.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15146294     DOI: 10.1007/s00262-004-0542-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  13 in total

1.  Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy.

Authors:  Paul Hatfield; Alison E Merrick; Emma West; Dearbhaile O'Donnell; Peter Selby; Richard Vile; Alan A Melcher
Journal:  J Immunother       Date:  2008-09       Impact factor: 4.456

2.  Activation outcomes induced in naïve CD8 T-cells by macrophages primed via "phagocytic" and nonphagocytic pathways.

Authors:  Isabel María Olazabal; Noa Beatriz Martín-Cofreces; María Mittelbrunn; Gloria Martínez del Hoyo; Balbino Alarcón; Francisco Sánchez-Madrid
Journal:  Mol Biol Cell       Date:  2007-12-12       Impact factor: 4.138

3.  Clinical significance of immunotherapy with combined three kinds of cells for operable colorectal cancer.

Authors:  Xiao-Hui Du; Hai-Liang Liu; Li Li; Shao-You Xia; Ning Ning; Zhen-Yu Zou; Da Teng; Chun-Hong Xiao; Rong Li; Ying-Xin Xu
Journal:  Tumour Biol       Date:  2015-03-13

4.  Potential target antigens for a universal vaccine in epithelial ovarian cancer.

Authors:  Renee Vermeij; Toos Daemen; Geertruida H de Bock; Pauline de Graeff; Ninke Leffers; Annechien Lambeck; Klaske A ten Hoor; Harry Hollema; Ate G J van der Zee; Hans W Nijman
Journal:  Clin Dev Immunol       Date:  2010-09-15

5.  Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.

Authors:  Jake Y Henry; Marie-Christine Labarthe; Brendan Meyer; Prokar Dasgupta; Angus G Dalgleish; Christine Galustian
Journal:  Immunology       Date:  2013-07       Impact factor: 7.397

6.  Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cells.

Authors:  Masahiro Azuma; Takashi Ebihara; Hiroyuki Oshiumi; Misako Matsumoto; Tsukasa Seya
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

7.  Identification of pancreatic cancer-associated tumor antigen from HSP-enriched tumor lysate-pulsed human dendritic cells.

Authors:  Han-Soo Kim; Dukjin Kang; Myeong Hee Moon; Hyung Jik Kim
Journal:  Yonsei Med J       Date:  2014-07       Impact factor: 2.759

8.  Fibroblast and T cells conditioned media induce maturation dendritic cell and promote T helper immune response.

Authors:  Masoumeh Asadi; Farah Farokhi; Nowruz Delirezh; Meysam Ganji Bakhsh; Vahid Nejati; Keykavos Golami
Journal:  Vet Res Forum       Date:  2012       Impact factor: 1.054

9.  The MHC class I peptide repertoire is molded by the transcriptome.

Authors:  Marie-Hélène Fortier; Etienne Caron; Marie-Pierre Hardy; Grégory Voisin; Sébastien Lemieux; Claude Perreault; Pierre Thibault
Journal:  J Exp Med       Date:  2008-02-25       Impact factor: 14.307

10.  Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.

Authors:  Fan-Qin Wei; Wei Sun; Thian-Sze Wong; Wei Gao; Yi-Hui Wen; Jia-Wei Wei; Yi Wei; Wei-Ping Wen
Journal:  J Exp Clin Cancer Res       Date:  2016-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.